Guest Editors
Prof. Maria Beatrice Morelli
Email: mariabeatrice.morelli@unicam.it
Affiliation: School of Pharmacy, University of Camerino, Camerino, 62032, Italy
Homepage:
Research Interests: cancer biology, anticancer therapies, personalized therapies, ion channel, cancer biomarkers
Dr. Cristina Aguzzi
Email: cristina.aguzzi@unicam.it
Affiliation: School of Pharmacy, University of Camerino, Camerino, 62032, Italy
Homepage:
Research Interests: cancer biology, multiple myeloma, anticancer therapies, metastasis, tumor microenvironment
Summary
Hematologic malignancies, including leukemias, lymphomas, and myelomas, represent a heterogeneous group of cancers with complex immune interactions that influence disease progression, prognosis, and therapeutic response. In recent years, research has increasingly focused on the immunopathological mechanisms underlying these malignancies, including the role of the tumor microenvironment, immune evasion strategies, and chronic inflammation. At the same time, novel therapeutic approaches, such as immune checkpoint inhibitors, bispecific antibodies, CAR-T cells, and small molecule modulators, are redefining treatment paradigms.
This Special Issue aims to collect cutting-edge research and reviews that explore the emerging immunopathological pathways involved in hematologic cancers, as well as the identification and validation of novel therapeutic targets. We particularly welcome studies focusing on less-explored immune mechanisms, resistance to immunotherapy, and translational research bridging preclinical findings to clinical application.
Contributions may include original research articles, mechanistic studies, preclinical models, as well as insightful reviews discussing current challenges and future directions. We encourage submissions that highlight innovative strategies or personalized approaches to immune modulation in hematologic cancers.
We warmly invite you to contribute to this Special Issue and join us in deepening the understanding of immune-related mechanisms and therapies in hematologic malignancies.
Keywords
hematologic malignancies, immunopathology, tumor microenvironment, immune evasion, inflammation and cancer, leukemia, lymphoma, multiple myeloma, immune checkpoints, CAR-T cell therapy, bispecific antibodies, cytokine signaling, immunotherapy resistance, targeted therapy, translational immunology, novel therapeutic targets, innate immunity in cancer, adaptive immunity, tumor-immune interactions
Login
Register
Submit a Paper
Propose a Special lssue